Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation

Clinical Pharmacokinetics

Volumn 43, Issue 10, 2004, Pages 623-653

  Staatz, Christine E ^a   Tett, Susan E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CALCINEURIN; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450 3A; GLYCOPROTEIN P; TACROLIMUS;

ALOPECIA; AREA UNDER THE CURVE; ASCITES; BLOOD SAMPLING; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CLINICAL TRIAL; CORRELATION ANALYSIS; CREATININE CLEARANCE; CYTOKINE PRODUCTION; DIABETOGENESIS; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENTIATION; DRUG TISSUE LEVEL; DYSARTHRIA; GASTROINTESTINAL SYMPTOM; GINGIVITIS; GRAFT REJECTION; HEADACHE; HEART TRANSPLANTATION; HEMATOCRIT; HEMOCONCENTRATION; HIGH RISK POPULATION; HIRSUTISM; HUMAN; HYPERESTHESIA; HYPERKALEMIA; HYPERPLASIA; HYPERTENSION; HYPOMAGNESEMIA; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; INTESTINE TRANSPLANTATION; JEJUNOILEOSTOMY; KIDNEY TRANSPLANTATION; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; LYMPHOMA; NEPHROTOXICITY; NEUROTOXICITY; NIGHTMARE; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PARESTHESIA; PHOTOPHOBIA; POPULATION RESEARCH; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREMOR;

DRUG INTERACTIONS; DRUG MONITORING; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; TACROLIMUS;

EID: 3242772986     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200443100-00001     Document Type: Review

References (329)

1. Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000; 59 (2): 323-89
2. Pham SM, Kormos RL, Kawai A, et al. Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience. Transplant Proc 1996; 28 (2): 1002-4
3. De Bonis M, Reynolds L, Barros J, et al. Tacrolimus as a rescue immunosuppressant after heart transplantation. Eur J Cardiothorac Surg 2001; 19 (5): 690-5
4. Crespo-Leiro MG, Paniagua MJ, Mosquera I, et al. Replacement of cyclosporine by tacrolimus for immunosuppression in heart transplant patients: safety and efficacy. Transplant Proc 2002; 34 (1): 113-4
5. Swenson JM, Fricker FJ, Armitage JM. Immunosuppression switch in pediatric heart transplant recipients: cyclosporine to FK 506. J Am Coll Cardiol 1995; 25 (5): 1183-8
6. Reyes J, Mazariegos GV, Bond GM, et al. Pediatric intestinal transplantation: historical notes, principles and controversies. Pediatr Transplant 2002; 6 (3): 193-207
7. Kato T, Ruiz P, Thompson JF, et al. Intestinal and multivisceral transplantation. World J Surg 2002; 26 (2): 226-37
8. Jindal RM, Dubernard JM. Towards a specific immunosuppression for pancreas and islet grafts. Clin Transplant 2000; 14 (3): 242-5
9. Stratta RJ. Optimal immunosuppression in pancreas transplantation. Transplant Proc 1999; 31 (1-2): 619-21
10. Stratta RJ, Taylor RJ, Castaldo P, et al. FK 506 induction and rescue therapy in pancreas transplant recipients. Transplant Proc 1996; 28 (2): 991-2
11. Gruessner RW. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Clin Transplant 1997; 11 (4): 299-312
12. Jordan ML, Shapiro R, Gritsch HA, et al. Long-term results of pancreas transplantation under tacrolimus immunosuppression. Transplantation 1999; 67 (2): 266-72
13. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92 (7): 2303-14
14. Fay JW, Wingard JR, Antin JH, et al. FK506 (tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. Blood 1996; 87 (8): 3514-9
15. Jacobson P, Uberti J, Davis W, et al. Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation. Bone Marrow Transplant 1998; 22 (3): 217-25
16. Lee TJ, Kennedy LA. Tacrolimus: an alternative for graft-versus-host disease prevention. Ann Pharmacother 2000; 34 (3): 377-81
17. Yanik G, Levine JE, Ratanatharathorn V, et al. Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation. Bone Marrow Transplant 2000; 26 (2): 161-7
18. Horning NR, Lynch JP, Sundaresan SR, et al. Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation. J Heart Lung Transplant 1998; 17 (8): 761-7
19. Kur F, Reichenspurner H, Meiser BM, et al. Tacrolimus (FK506) as primary immunosuppressant after lung transplantation. Thorac Cardiovasc Surg 1999; 47 (3): 174-8
20. Lipson DA, Palevsky HI, Kotloff RM, et al. Conversion to tacrolimus (FK506) from cyclosporine after orthotopic lung transplantation. Transplant Proc 1998; 30 (4): 1505-7
21. Reichenspurner H, Kur F, Treede H, et al. Optimization of the immunosuppressive protocol after lung transplantation. Transplantation 1999; 68 (1): 67-71
22. Treede H, Klepetko W, Reichenspurner H, et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. J Heart Lung Transplant 2001; 20 (5): 511-7
23. Busuttil RW, Holt CD. Tacrolimus is superior to cyclosporine in liver transplantation. Transplant Proc 1998; 30 (5): 2174-8
24. Cao S, Cox KL, Berquist W, et al. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus. Pediatr Transplant 1999; 3 (1): 22-6
25. McDiarmid SV. The use of tacrolimus in pediatric liver transplantation. J Pediatr Gastroenterol Nutr 1998; 26 (1): 90-102
26. Reyes J, Jain A, Mazariegos G, et al. Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. Transplantation 2000; 69 (12): 2573-80
27. Berloco P, Rossi M, Pretagostini R, et al. Tacrolimus as cornerstone immunosuppressant in kidney transplantation. Transplant Proc 2001; 33 (1-2): 994-6
28. Laskow DA, Neylan JF, Shapiro RS, et al. The role of tacrolimus in adult kidney transplantation: a review. Clin Transplant 1998; 12 (6): 489-503
29. Shapiro R. Tacrolimus in solid organ transplantation: an update. Transplant Proc 1999; 31 (6): 2203-5
30. Shapiro R. Tacrolimus in pediatric renal transplantation: a review. Pediatr Transplant 1998; 2 (4): 270-6
31. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29 (6): 404-30
32. Trull AK. Therapeutic monitoring of tacrolimus. Ann Clin Biochem 1998; 35 (Pt 2): 167-80
33. Taylor DO, Barr ML, Meiser BM, et al. Suggested guidelines for the use of tacrolimus in cardiac transplant recipients. J Heart Lung Transplant 2001; 20 (7): 734-8
34. Walker S, Habib S, Rose M, et al. Clinical use and bioavailability of tacrolimus in heart-lung and double lung transplant recipients with cystic fibrosis. Transplant Proc 1998; 30 (4): 1519-20
35. Tacrolimus (Prograf®): prescribing information. Deerfield (IL): Fujisawa Healthcare Inc., Aug 2003 [online]. Available from URL: http://www.fujisawa.com/medinfo/pi/pi_main_pg.htm [Accessed 2004 Jun 14]
36. van Hooff JP, Boots JM, van Duijnhoven EM, et al. Dosing and management guidelines for tacrolimus in renal transplant patients. Transplant Proc 1999; 31 (7A): 54-7S
37. Busuttil RW, Klintmalm GB, Lake JR, et al. General guidelines for the use of tacrolimus in adult liver transplant patients. Transplantation 1996; 61 (5): 845-7
38. Garrity ER, Hertz MI, Trulock EP, et al. Suggested guidelines for the use of tacrolimus in lung-transplant recipients. J Heart Lung Transplant 1999; 18 (3): 175-6
39. Gruessner RW, Bartlett ST, Burke GW, et al. Suggested guidelines for the use of tacrolimus in pancreas/kidney transplantation. Clin Transplant 1998; 12 (3): 260-2
40. Ellis D. Clinical use of tacrolimus (FK-506) in infants and children with renal transplants. Pediatr Nephrol 1995; 9 (4): 487-94
41. Esquivel CO, So SK, McDiarmid SV, et al. Suggested guidelines for the use of tacrolimus in pediatric liver transplant patients. Transplantation 1996; 61 (5): 847-8
42. van Mourik ID, Kelly DA. Immunosuppressive drugs in paediatric liver transplantation. Paediatr Drugs 2001; 3 (1): 43-60
43. Furlan V, Debray D, Fourre C, et al. Conversion from cyclosporin A to tacrolimus in pediatric liver transplantation. Pediatr Transplant 2000; 4 (3): 207-10
44. Gaston RS. Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis 2001; 38 (6 Suppl. 6): S25-35
45. Kokado Y, Takahara S, Kyo M, et al. Low-dose tacrolimus (FK506)-based immunosuppressive protocol in living donor renal transplantation. Transpl Int 1998; 11 Suppl. 1: S60-4
46. Hasegawa A, Takahashi K, Ito K, et al. Optimal use of tacrolimus in living donor renal transplantation in children. Transplant Proc 2002; 34 (5): 1939-41
47. Wallemacq PE, Furlan V, Moller A, et al. Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients. Eur J Drug Metab Pharmacokinet 1998; 23 (3): 367-70
48. Gruber SA, Hewitt JM, Sorenson AL, et al. Pharmacokinetics of FK506 after intravenous and oral administration in patients awaiting renal transplantation. J Clin Pharmacol 1994; 34 (8): 859-64
49. Jain A, Venkataramanan R, Todo S, et al. Intravenous, oral pharmacokinetics, and oral dosing of FK 506 in small bowel transplant patients. Transplant Proc 1992; 24 (3): 1181-2
50. Fitzsimmons WE, Bekersky I, Dressler D, et al. Demographic considerations in tacrolimus pharmacokinetics. Transplant Proc 1998; 30 (4): 1359-64
51. Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 1998; 65 (4): 515-23
52. Neylan JF. Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group. Transplant Proc 1998; 30 (4): 1355-8
53. Mancinelli LM, Frassetto L, Floren LC, et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 2001; 69 (1): 24-31
54. Felipe CR, Garcia C, Moreira S, et al. Choosing the right dose of new immunosuppressive drugs for new populations: importance of pharmacokinetic studies. Transplant Proc 2001; 33 (1-2): 1095-6
55. van Duijnhoven E, Christiaans M, Schafer A, et al. Tacrolimus dosing requirements in diabetic and nondiabetic patients calculated from pretransplantation data. Transplant Proc 1998; 30 (4): 1266-7
56. Hu RH, Lee PH, Tsai MK. Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients. Transplant Proc 2000; 32 (7): 1689-92
57. Mekki Q, Lee CC, Carrier S, et al. The effect of food on oral bioavailability of tacrolimus (FK506) in liver transplant patients [abstract]. Clin Pharmacol Ther 1993; 53 (2): 229
58. Bekersky I, Dressler D, Mekki QA. Effect of low- and high-fat meals on tacrolimus absorption following 5mg single oral doses to healthy human subjects. J Clin Pharmacol 2001; 41 (2): 176-82
59. Bekersky I, Dressler D, Mekki Q. Effect of time of meal consumption on bioavailability of a single oral 5mg tacrolimus dose. J Clin Pharmacol 2001; 41 (3): 289-97
60. Venkataramanan R, Jain A, Warty VS, et al. Pharmacokinetics of FK 506 in transplant patients. Transplant Proc 1991; 23 (6): 2736-40
61. Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995; 57 (3): 281-90
62. Tuteja S, Alloway RR, Johnson JA, et al. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 2001; 71 (9): 1303-7
63. Benet LZ. Impact of intraindividual variability of drugs on therapeutic outcomes: lessons from outside transplantation. Transplant Proc 1998; 30 (5): 1650-1
64. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40 (3): 159-68
65. Lampen A, Christians U, Guengerich FP, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995; 23 (12): 1315-24
66. Lampen A, Christians U, Gonschior AK, et al. Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. Br J Pharmacol 1996; 117 (8): 1730-4
67. Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 283 (3): 1552-62
68. Wacher VJ, Silverman JA, Zhang Y, et al. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998; 87 (11): 1322-30
69. de Waziers I, Cugnenc PH, Yang CS, et al. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 1990; 253 (1): 387-94
70. Benet LZ, Izumi T, Zhang Y, et al. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 1999; 62 (1-2): 25-31
71. Gan LS, Moseley MA, Khosla B, et al. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab Dispos 1996; 24 (3): 344-9
72. Lo A, Burckart G. P-glycoprotein and drug therapy in organ transplantation. J Clin Pharmacol 1999; 39: 995-1005
73. Fojo AT, Ueda K, Slamon DJ, et al. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 1987; 84 (1): 265-9
74. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62 (3): 248-60
75. Venkataramanan R, Jain A, Warty VW, et al. Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. Transplant Proc 1991; 23 (1 Pt 2): 931-3
76. Jain AB, Venkataramanan R, Cadoff E, et al. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc 1990; 22 (1): 57-9
77. Bottiger Y, Undre N, Sawe J, et al. Effect of bile flow on the absorption of tacrolimus in liver allograft transplantation. Transplant Proc 2002; 34 (5): 1544-5
78. Murray M, Grogan TA, Lever J, et al. Comparison of tacrolimus absorption in transplant patients receiving continuous versus interrupted enterai nutritional feeding. Ann Pharmacother 1998; 32 (6): 633-6
79. Warty VS, Venkataramanan R, Zendehrouh P, et al. Practical aspects of FK 506 analysis (Pittsburgh experience). Transplant Proc 1991; 23 (6): 2730-1
80. Jusko WJ, D'Ambrosio R. Monitoring FK 506 concentrations in plasma and whole blood. Transplant Proc 1991; 23 (6): 2732-5
81. Beysens AJ, Wijnen RM, Beuman GH, et al. FK 506: monitoring in plasma or in whole blood? Transplant Proc 1991; 23 (6): 2745-7
82. Jusko WJ. Analysis of tacrolimus (FK 506) in relation to therapeutic drug monitoring. Ther Drug Monit 1995; 17 (6): 596-601
83. Ericzon BG, Ekqvist B, Groth CG, et al. Pharmacokinetics of FK 506 during maintenance therapy in liver transplant patients. Transplant Proc 1991; 23 (6): 2775-6
84. Machida M, Takahara S, Ishibashi M, et al. Effect of temperature and hematocrit on plasma concentration of FK 506. Transplant Proc 1991; 23 (6): 2753-4
85. Nagase K, Iwasaki K, Nozaki K, et al. Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. J Pharm Pharmacol 1994; 46 (2): 113-7
86. Kay JE, Sampare-Kwateng E, Geraghty F, et al. Uptake of FK 506 by lymphocytes and erythrocytes. Transplant Proc 1991; 23 (6): 2760-2
87. Kobayashi M, Tamura K, Katayama N, et al. FK 506 assay past and present-characteristics of FK 506 ELISA. Transplant Proc 1991; 23 (6): 2725-9
88. Piekoszewski W, Chow FS, Jusko WJ. Disposition of tacrolimus (FK 506) in rabbits: role of red blood cell binding in hepatic clearance. Drug Metab Dispos 1993; 21 (4): 690-8
89. Jain A, Venkataramanan R, Lever J, et al. FK506 and pregnancy in liver transplant patients. Transplantation 1993; 56 (6): 1588-9
90. Jain A, Venkataramanan R, Fung JJ, et al. Pregnancy after liver transplantation under tacrolimus. Transplantation 1997; 64 (4): 559-65
91. Jain AB, Fung JJ, Tzakis AG, et al. Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. Transplant Proc 1991; 23 (6): 2763-6
92. Wallemacq PE, Verbeeck RK. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet 2001; 40 (4): 283-95
93. 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos 1999; 27 (6): 633-6
94. Wrighton SA, VandenBranden M, Ring BJ. The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm 1996; 24 (5): 461-73
95. de Wildt SN, Kearns GL, Leeder JS, et al. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999; 37 (6): 485-505
96. Karanam BV, Vincent SH, Newton DJ, et al. FK 506 metabolism in human liver microsomes: investigation of the involvement of cytochrome P450 isozymes other than CYP3A4. Drug Metab Dispos 1994; 22 (5): 811-4
97. Lemoine A, Azoulay D, Gries JM, et al. Relationship between graft cytochrome P-450 3A content and early morbidity after liver transplantation. Transplantation 1993; 56 (6): 1410-4
98. Sattler M, Guengerich FP, Yun CH, et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992; 20 (5): 753-61
99. Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 1996; 24 (5): 475-90
100. Gellner KR, Eiselt R, Hustert E, et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 2001; 11 (2): 111-21
101. Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54 (10): 1271-94
102. Wrighton SA, Brian WR, Sari MA, et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990; 38 (2): 207-13
103. Schuetz JD, Molowa DT, Guzelian PS. Characterization of a cDNA encoding a new member of the glucocorticoid-responsive cytochromes P450 in human liver. Arch Biochem Biophys 1989; 274 (2): 355-65
104. Tateishi T, Watanabe M, Moriya H, et al. No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. Biochem Pharmacol 1999; 57 (8): 935-9
105. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27 (4): 383-91
106. Lin YS, Dowling AL, Quigley SD, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62 (1): 162-72
107. Domanski TL, Finta C, Halpert JR, et al. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 2001; 59 (2): 386-92
108. Westlind A, Malmebo S, Johansson I, et al. Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 2001; 281 (5): 1349-55
109. Christians U, Braun F, Kosian N, et al. High performance liquid chromatography/mass spectrometry of FK 506 and its metabolites in blood, bile, and urine of liver grafted patients. Transplant Proc 1991; 23 (6): 2741-4
110. Christians U, Kruse C, Kownatzki R, et al. Measurement of FK 506 by HPLC and isolation and characterization of its metabolites. Transplant Proc 1991; 23 (1 Pt 2): 940-1
111. Christians U, Radeke HH, Kownatzki R, et al. Isolation of an immunosuppressive metabolite of FK506 generated by human microsome preparations. Clin Biochem 1991; 24 (3): 271-5
112. Christians U, Braun F, Schmidt M, et al. Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver-graft recipients. Clin Chem 1992; 38 (10): 2025-32
113. Iwasaki K, Shiraga T, Matsuda H, et al. Further metabolism of FK506 (tacrolimus): identification and biological activities of the metabolites oxidized at multiple sites of FK506. Drug Metab Dispos 1995; 23 (1): 28-34
114. Alak AM, Moy S. Biological activity of tacrolimus (FK506) and its metabolites from whole blood of kidney transplant patients. Transplant Proc 1997; 29 (5): 2487-90
115. Gonschior AK, Christians U, Winkler M, et al. Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. Clin Chem 1996; 42 (9): 1426-32
116. Venkataramanan R, Jain AK, Lever J, et al. Pharmacokinetics of tacrolimus (Tac) in transplant patients [abstract]. Ther Drug Monit 1995; 17 (4): 416
117. Gonschior AK, Christians U, Braun F, et al. Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA). Br J Clin Pharmacol 1994; 38 (6): 567-71
118. Iwasaki K, Shiraga T, Nagase K, et al. Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. Drug Metab Dispos 1993; 21 (6): 971-7
119. Boswell GW, Bekersky I, Fay J, et al. Tacrolimus pharmacokinetics in BMT patients. Bone Marrow Transplant 1998; 21 (1): 23-8
120. Mekki QA, Piscitelli D, Fitzsimmons WE. Pharmacokinetics of tacrolimus in bone marrow transplant patients [abstract]. Clin Pharmacol Ther 1993; 55 (2): 149
121. Bekersky I, Dressler D, Alak A, et al. Comparative tacrolimus pharmacokinetics: normal versus mildly hepatically impaired subjects. J Clin Pharmacol 2001; 41 (6): 628-35
122. Hebert MF, Fisher RM, Marsh CL, et al. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999; 39 (1): 91-6
123. Steinmuller DR. FK506 and organ transplantation. Austin (TX): Medical Intelligence Unit, RG Landers Co, 1994: 1-111
124. Venkataramanan R, Jain A, Lever J, et al. High dose tacrolimus requirements in transplant patients [abstract]. Pharm Res 1994; 7: 329-33
125. Satoh S, Tada H, Tachiki Y, et al. Chrono and clinical pharmacokinetic study of tacrolimus in continuous intravenous administration. Int J Urol 2001; 8 (7): 353-8
126. Aweeka FT, Benet LZ, Gambertoglio JG, et al. Comparitive pharmacokinetics of orally (PO) and intravenously (IV) administered tacrolimus (FK506) in pre- and post-kidney transplant recipients [abstract]. Clin Pharmacol Ther 1993; 53 (2): 151
127. Lee CC, Hewitt JM, Aweeka FT, et al. Pharmacokinetics of tacrolimus (FK506) prior to kidney transplantation [abstract]. Clin Pharmacol Ther 1993; 53 (2): 238
128. Saito K, Suwa M, Nakagawa Y, et al. Study of pharmacokinetic parameters of tacrolimus by different oral administration periods in renal transplantation. Transplant Proc 2002; 34 (5): 1726-9
129. Mekki QA, Lee CC, Aweeka FT, et al. Pharmacokinetics of tacrolimus (FK506) in kidney transplant patients [abstract]. Clin Pharmacol Ther 1993; 53 (2): 238
130. Tuteja S, Alloway RR, Johnson JA, et al. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 2001; 71 (9): 1303-7
131. Lee CC, Jusko WJ, Shaefer MS, et al. Pharmacokinetics of tacrolimus (FK506) in liver transplant patients [abstract]. Clin Pharmacol Ther 1993; 53 (2): 181
132. Jain A, Venkataramanan R, Lever J, et al. FK 506 in small bowel transplant recipients: pharmacokinetics and dosing. Transplant Proc 1994; 26 (3): 1609-10
133. Venkataramanan R, Jain A, Cadoff E, et al. Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc 1990; 22 (1): 52-6
134. Shishido S, Asanuma H, Tajima E, et al. Pharmacokinetics of tacrolimus in pediatric renal transplant recipients. Transplant Proc 2001; 33 (1-2): 1066-8
135. Webb N, Stevenson P, Lewis M, et al. Pharmacokinetics of tacrolimus in paediatric renal transplant recipients. Transplant Proc 2002; 34 (5): 1948-50
136. Sewing KF. Pharmacokinetics, dosing principles, and blood level monitoring of FK506. Transplant Proc 1994; 26 (6): 3267-9
137. Regazzi MB, Rinaldi M, Molinaro M, et al. Clinical pharmacokinetics of tacrolimus in heart transplant recipients. Ther Drug Monit 1999; 21 (1): 2-7
138. Molinaro M, Regazzi MB, Pasquino S, et al. Pharmacokinetics of tacrolimus during the early phase after heart transplantation. Transplant Proc 2001; 33 (3): 2386-9
139. Undre N, Stevenson P. Pharmacokinetics of tacrolimus in heart transplantation. Transplant Proc 2002; 34 (5): 1836-8
140. Mehta P, Beltz S, Kedar A, et al. Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation. Bone Marrow Transplant 1999; 24 (12): 1323-7
141. Jusko WJ, Thomson AW, Fung J, et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit 1995; 17 (6): 606-14
142. Kuzuya T, Ogura Y, Motegi Y, et al. Interference of hematocrit in the tacrolimus II microparticle enzyme immunoassay. Ther Drug Monit 2002; 24 (4): 507-11
143. McMasters P, Mirza DF, Ismail T, et al. Therapeutic drug monitoring of tacrolimus in clinical transplantation. Ther Drug Monit 1995; 17 (6): 602-5
144. Christians U, Jacobsen W, Benet LZ, et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41 (11): 813-51
145. Jain AB, Abu-Elmagd K, Abdallah H, et al. Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. J Clin Pharmacol 1993; 33 (7): 606-11
146. Abu-Elmagd K, Fung JJ, Alessiani M, et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation 1991; 52 (1): 71-7
147. Abu-Elmagd KM, Fung JJ, Alessiani M, et al. Strategy of FK 506 therapy in liver transplant patients: effect of graft function. Transplant Proc 1991; 23 (6): 2771-4
148. Pou L, Brunet M, Andres I, et al. Influence of posttransplant time on dose and concentration of tacrolimus in liver transplant patients. Transpl Int 1998; 11 Suppl. 1: S270-1
149. Manzanares C, Moreno M, Castellanos F, et al. Influence of hepatitis C virus infection on FK 506 blood levels in renal transplant patients. Transplant Proc 1998; 30 (4): 1264-5
150. van den Berg AP, Haagsma EB, Gouw AS, et al. Recurrent HCV infection reduces the requirement for tacrolimus after liver transplantation. Transplant Proc 2001; 33 (1-2): 1467
151. Moreno M, Manzanares C, Castellano F, et al. Monitoring of tacrolimus as rescue therapy in pediatric liver transplantation. Ther Drug Monit 1998; 20 (4): 376-9
152. Horina JH, Wirnsberger GH, Kenner L, et al. Increased susceptibility for CsA-induced hepatotoxicity in kidney graft recipients with chronic viral hepatitis C. Transplantation 1993; 56 (5): 1091-4
153. Undre NA, Schafer A. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. Transplant Proc 1998; 30 (4): 1261-3
154. Christiaans M, van Duijnhoven E, Beysens T, et al. Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. Transplant Proc 1998; 30 (4): 1271-3
155. McDiarmid SV, Colonna JO, Shaked A, et al. Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients. Transplantation 1993; 55 (6): 1328-32
156. Satomura K, Ozaki N, Okajima H, et al. Pharmacokinetics of FK 506 in living-related liver transplantation. Transplant Proc 1996; 28 (2): 1005
157. Yasuhara M, Hashida T, Toraguchi M, et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. Transplant Proc 1995; 27(1): 1108-10
158. Uemoto S, Tanaka K, Honda K, et al. Experience with FK506 in living-related liver transplantation. Transplantation 1993; 55 (2): 288-92
159. Cacciarelli TV, Esquivel CO, Cox KL, et al. Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. Transplantation 1996; 61 (8): 1188-92
160. MacFarlane GD, Venkataramanan R, McDiarmid SV, et al. Therapeutic drug monitoring of tacrolimus in pediatric liver transplant patients. Pediatr Transplant 2001; 5 (2): 119-24
161. Przepiorka D, Blamble D, Hilsenbeck S, et al. Tacrolimus clearance is age-dependent within the pediatric population. Bone Marrow Transplant 2000; 26 (6): 601-5
162. Mittal N, Thompson JF, Kato T, et al. Tacrolimus and diarrhea: pathogenesis of altered metabolism. Pediatr Transplant 2001; 5 (2): 75-9
163. Teperman LW, Morgan GR, Diflo T, et al. Tacrolimus dose is donor age dependent [abstract]. 24th Annual Scientific Meeting of the American Society of Transplant Surgeons; 1998 May 13-15; Chicago
164. Taber DJ, Dupuis RE, Fann AL, et al. Tacrolimus dosing requirements and concentrations in adult living donor liver transplant recipients. Liver Transpl 2002; 8 (3): 219-23
165. Trotter JF, Stolpman N, Wachs M, et al. Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients. Liver Transpl 2002; 8 (3): 212-8
166. Troisi R, Militerno G, Hoste E, et al. Are reduced tacrolimus dosages needed in the early postoperative period following living donor liver transplantation in adults? Transplant Proc 2002; 34 (5): 1531-2
167. Harihara Y, Sano K, Makuuchi M, et al. Correlation between graft size and necessary tacrolimus dose after living-related liver transplantation. Transplant Proc 2000; 32 (7): 2166-7
168. Sugawara Y, Makuuchi M, Kaneko J, et al. Correlation between optimal tacrolimus doses and the graft weight in living donor liver transplantation. Clin Transplant 2002; 16 (2): 102-6
169. Nakazawa Y, Chisuwa H, Ikegami T, et al. Relationship between in vivo FK506 clearance and in vitro 13-demethylation activity in living-related liver transplantation. Transplantation 1998; 66 (8): 1089-93
170. Felipe CR, Silva HT, Machado PG, et al. The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring. Clin Transplant 2002; 16 (4): 262-72
171. Uber PA, Mehra MR, Scott RL, et al. Ethnic disparities in the pharmacologic characteristics of tacrolimus in heart transplantation. Transplant Proc 2001; 33 (1-2): 1581-2
172. Huang ML, Venkataramanan R, Burckart GJ, et al. Drug-binding proteins in liver transplant patients. J Clin Pharmacol 1988; 28 (6): 505-6
173. Min DI, Chen HY, Fabrega A, et al. Circadian variation of tacrolimus disposition in liver allograft recipients. Transplantation 1996; 62 (8): 1190-2
174. Kimikawa M, Kamoya K, Toma H, et al. Effective oral administration of tacrolimus in renal transplant recipients. Clin Transplant 2001; 15 (5): 324-9
175. van Duijnhoven E, Christiaans M, Boots J, et al. Evidence that fasting does not significantly affect trough levels of tacrolimus in stable renal transplant recipients. Transplant Proc 2002; 34 (5): 1723-5
176. Eades SK, Boineau FG, Christensen ML. Increased tacrolimus levels in a pediatric renal transplant patient attributed to chronic diarrhea. Pediatr Transplant 2000; 4 (1): 63-6
177. Hochleitner BW, Bosmuller C, Nehoda H, et al. Increased tacrolimus levels during diarrhea. Transpl Int 2001; 14 (4): 230-3
178. Matsui A, Arakawa Y, Momoya T, et al. Apparently increased trough levels of tacrolimus caused by acute infantile diarrhea in two infants with biliary atresia after liver transplantation. Acta Paediatr Jpn 1996; 38 (6): 699-701
179. Fruhwirth M, Fischer H, Simma B, et al. Rotavirus infection as cause of tacrolimus elevation in solid-organ- transplanted children. Pediatr Transplant 2001; 5 (2): 88-92
180. Fruhwirth M, Fischer H, Simma B, et al. Elevated tacrolimus trough levels in association with mycophenolate mofetil-induced diarrhea: a case report. Pediatr Transplant 2001; 5 (2): 132-4
181. Zylber-Katz E, Granot E. Abrupt increase of tacrolimus blood levels during an episode of Shigella infection in a child after liver transplantation. Ther Drug Monit 2001; 23 (6): 647-9
182. Itagaki F, Hori T, Tomita T, et al. Effect of ascites on tacrolimus disposition in a liver transplant recipient. Ther Drug Monit 2001; 23 (6): 644-6
183. Novelli M, Muiesan P, Mieli-Vergani G, et al. Oral absorption of tacrolimus in children with intestinal failure due to short or absent small bowel. Transpl Int 1999; 12 (6): 463-5
184. Hasegawa T, Nara K, Kimura T, et al. Oral administration of tacrolimus in the presence of jejunostomy after liver transplantation. Pediatr Transplant 2001; 5 (3): 204-9
185. Zheng H, Webber S, Zeevi A, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 2003; 3 (4): 477-83
186. MacPhee IA, Fredericks S, Tai T, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004; 4 (6): 914-9
187. McPhee IA, Fredericks S, Tai T, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74 (11): 1486-9
188. Hesselink DA, van Schaik RHN, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5 and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors and cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74 (3): 245-54
189. de Wildt SN, Kearns GL, Leeder JS, et al. Cytochrome P4503A: ontogeny and drug disposition. Clin Pharmacokinet 1999; 37 (6): 485-505
190. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27 (4): 383-91
191. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11 (9): 773-9
192. Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54 (10): 1271-94
193. Amirimani B, Walker AH, Weber BL, et al. Response: modification of clinical presentation of prostrate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1999; 91: 1588-90
194. Kurata Y, Ieiri I, Kimura M, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002; 72 (2): 209-19
195. Chowbay B, Cumaraswamy S, Cheung YB, et al. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003; 13 (2): 89-95
196. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97 (7): 3473-8
197. Lin JH, Yamazaki M. Role of p-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003; 42 (1): 59-98
198. Fredericks S, Holt DW, MacPhee IAM. The pharmacogenetics of immunosuppression for organ transplantation. Am J Pharmacogenomics 2003; 3 (5): 291-301
199. Kaplan B, Lown K, Craig R, et al. Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. Transplantation 1999; 67 (2): 333-5
200. Hashida T, Masuda S, Uemoto S, et al. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther 2001; 69 (5): 308-16
201. Masuda S, Uemoto S, Hashida T, et al. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin Pharmacol Ther 2000; 68 (1): 98-103
202. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997; 27 (2-3): 201-14
203. Tett SE, Holford NHG, McLachlan AJ. Population pharmacokinetics and pharmacodynamics: an underutilized resource. Drug Inf J 1998; 32: 693-710
204. Minto C, Schnider T. Expanding clinical applications of population pharmacodynamic modelling. Br J Clin Pharmacol 1998; 46 (4): 321-33
205. Williams PJ, Ette EI. The role of population pharmacokinetics in drug development in light of the Food and Drug Administration's 'Guidance for Industry: population pharmacokinetics'. Clin Pharmacokinet 2000; 39 (6): 385-95
206. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977; 5 (5): 445-79
207. Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 1992; 22 (6): 447-67
208. Sam WJ, Aw M, Quak SH, et al. Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. Br J Clin Pharmacol 2000; 50 (6): 531-41
209. Garcia Sanchez MJ, Manzanares C, Santos-Buelga D, et al. Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy. Clin Pharmacokinet 2001; 40 (1): 63-71
210. Staatz CE, Taylor PJ, Lynch SV, et al. Population pharmacokinetics of tacrolimus in children who receive cut- down or full liver transplants. Transplantation 2001; 72 (6): 1056-61
211. Mekki QA, Lee CC. Population pharmacokinetics of tacrolimus (FK506) in liver transplant patients [abstract]. Clin Pharmacol Ther 1994; 55 (2): 162
212. Bruce NJ, Thomson AH, Elliott HL. Population pharmacokinetics of tacrolimus in liver transplant patients [online]. Available from URL: http://www.page-meeting.org/page/page95/abstract/abstract.html [Accessed 2004 Jun 24]
213. Macchi-Andanson M, Charpiat B, Jelliffe RW, et al. Failure of traditional trough levels to predict tacrolimus concentrations. Ther Drug Monit 2001; 23 (2): 129-33
214. Staatz CE, Willis C, Taylor PJ, et al. Towards better outcomes with tacrolimus therapy: population pharmacokinetics and individualised dosage prediction in adult liver transplantation. Liver Transpl 2003; 9: 130-7
215. Fukatsu S, Yano I, Igarashi T, et al. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol 2001; 57 (6-7): 479-84
216. Staatz CE, Willis C, Taylor PJ, et al. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 2002; 72 (6): 660-9
217. Willis C, Staatz CE, Tett SE. Bayesian forecasting and prediction of tacrolimus concentrations in pediatric liver and adult renal transplant recipients. Ther Drug Monit 2003; 25: 158-66
218. Prasad TN, Stiff DD, Subbotina N, et al. FK 506 (tacrolimus) metabolism by rat liver microsomes and its inhibition by other drugs. Res Commun Chem Pathol Pharmacol 1994; 84 (1): 35-46
219. Christians U, Schmidt G, Bader A, et al. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol 1996; 41 (3): 187-90
220. Iwasaki K, Matsuda H, Nagase K, et al. Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. Res Commun Chem Pathol Pharmacol 1993; 82 (2): 209-16
221. Matsuda H, Iwasaki K, Shiraga T, et al. Interactions of FK506 (tacrolimus) with clinically important drugs. Res Commun Mol Pathol Pharmacol 1996; 91(1): 57-64
222. Mignat C. Clinically significant drug interactions with new immunosuppressive agents. Drug Saf 1997; 16 (4): 267-78
223. Rui X, Flowers J, Warty V, et al. Drug interactions with FK506 [abstract]. Pharm Res 1992; 9 (10): S314
224. Spencer CM, Goa KL, Gillis JC. Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997; 54 (6): 925-75
225. Van Gelder T. Drug interactions with tacrolimus. Drug Saf 2002; 25 (10): 707-12
226. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423-8
227. The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110-5
228. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64 (3): 436-43
229. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63 (7): 977-83
230. Williams R, Neuhaus P, Bismuth H, et al. Two-year data from the European multicentre tacrolimus (FK506) liver study. Transpl Int 1996; 9 Suppl. 1: S144-50
231. Mor E, Yussim A, Chodoff L, et al. New immunosuppressive agents for maintenance therapy in organ transplantation: focus on adverse effects. BioDrugs 1997; 16 (4): 242-57
232. Henry ML. Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. Clin Transplant 1999; 13 (3): 209-20
233. Fung JJ, Todo S, Tzakis A, et al. Conversion of liver allograft recipients from cyclosporine to FK 506- based immunosuppression: benefits and pitfalls. Transplant Proc 1991; 23 (1 Pt 1): 14-21
234. Jain A, McCauley J, Kashyap R. Incidence of end-stage renal failure amongst long-term survival of primary liver transplant recipients under tacrolimus: adults and children [abstract]. Transplantation 1998; 65: S24
235. Kelly PA, Burckart GJ, Venkataramanan R. Tacrolimus: a new immuosuppressive agent. Am J Health Syst Pharm 1995; 52 (14): 1521-35
236. Eidelman BH, Abu-Elmagd K, Wilson J, et al. Neurologic complications of FK 506. Transplant Proc 1991; 23 (6): 3175-8
237. Chang CWJ. Neurological complications of critical illness and transplantation. Curr Opin Crit Care 1999; 5 (2): 112-8
238. Mueller AR, Platz KP, Christe W, et al. Severe neurotoxicity after liver transplantation: association between FK 506 therapy and hepatitis C virus disease. Transplant Proc 1994; 26 (6): 3131-2
239. Jindal RM, Sidner RA, Milgrom ML. Post-transplant diabetes mellitus: the role of immunosuppression. Drug Saf 1997; 16 (4): 242-57
240. Bonomini V, for the Italian-Spanish Tacrolimus Study Group. Low rejection rates with tacrolimus-based dual and triple regimens following renal transplantation [abstract]. J Am Soc Nephrol 1999; 10: 720A
241. Peters DH, Fitton A, Plosker GL, et al. Tacrolimus: a review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993; 46 (4): 746-94
242. Abouljoud MS, Levy MF, Klintmalm GB. Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter trial. US Multicenter Study Group. Transplant Proc 1995; 27 (1): 1121-3
243. Burke GW, Ciancio G, Alejandro R, et al. Cholesterol control: long-term benefit of pancreas-kidney transplantation with FK 506 immunosuppression. Transplant Proc 1998; 30 (2): 513-4
244. Canzanello VJ, Schwartz L, Taler SJ, et al. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). Liver Transpl Surg 1997; 3 (1): 1-9
245. Claesson K, Mayer AD, Squifflet JP, et al. Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients. Transplant Proc 1998; 30 (4): 1292-4
246. Friemann S, Feuring E, Padberg W, et al. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. Transplant Proc 1998; 30 (4): 1240-2
247. Guckelberger O, Bechstein WO, Neuhaus R, et al. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation. Clin Transplant 1997; 11 (1): 60-5
248. McCune TR, Thacker LR, Peters TG, et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. Transplantation 1998; 65 (1): 87-92
249. Penson MG, Winter WE, Fricker FJ, et al. Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients. J Heart Lung Transplant 1999; 18 (7): 707-13
250. Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18 (4): 336-45
251. Varghese Z, Fernando RL, Turakhia G, et al. Oxidizability of low-density lipoproteins from Neoral and tacrolimus- treated renal transplant patients. Transplant Proc 1998; 30 (5): 2043-6
252. Fagiuoli S, Gasbarrini A, Azzarone A, et al. FK 506: a new immunosuppressive agent for organ transplantation: pharmacology, mechanism of action and clinical applications. Ital J Gastroenterol 1992; 24 (6): 355-60
253. Li PKT, Nicholls MG, Lai KN. The complications of newer transplant antirejection drugs: treatment with cyclosporin-A, OKT-3 and FK506. Adverse Drug React Acute Poisoning Rev 1990; 9: 123-55
254. McCauley J, Fung J, Jain A, et al. The effects of FK 506 on renal function after liver transplantation. Transplant Proc 1990; 22 (1): 17-20
255. Niederstadt C, Steinhoff J, Erbsloh-Moller B, et al. Effect of FK506 on magnesium homeostasis after renal transplantation. Transplant Proc 1997; 29 (7): 3161-2
256. Mayer AD. Four-year follow-up of the European Tacrolimus Multicenter Renal Study. Transplant Proc 1999; 31 (7A): 27-8S
257. Tzakis AG, Fung JJ, Todo S, et al. Use of FK 506 in pediatric patients. Transplant Proc 1991; 23 (1 Pt 2): 924-7
258. Tzakis AG, Reyes J, Todo S, et al. Two-year experience with FK 506 in pediatric patients. Transplant Proc. 1993; 25 (1 Pt 1): 619-21
259. Sokal EM, Antunes H, Beguin C, et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation 1997; 64 (10): 1438-42
260. Shapiro R, Scantlebury VP, Jordan ML, et al. Pediatric renal transplantation under tacrolimus-based immunosuppression. Transplantation 1999; 67 (2): 299-303
261. Jain A, Reyes J, Kashyap R, et al. Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients. Transplant Proc 1998; 30 (4): 1403-4
262. Inomata Y, Tanaka K, Egawa H, et al. The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. Transplantation 1996; 61 (2): 247-52
263. So S, The US Multicentre FK506 Liver Study Group. Posttransplant lymphoproliferative disease (PTLD) in tacrolimus-treated liver transplant patients [abstract 207]. Proceedings of the 15th Annual Meeting of the American Society of Transplant Physicians; 1996 May 26-30; Dallas: 136
264. Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation: interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996; 62 (3): 370-5
265. Paolillo JA, Wagner K, Boyle GE, et al. Post-transplant diabetes mellitus in paediatric thoracic organ recipients receiving tacrolimus-based immunosuppression [abstract]. Transplantation 1999; 67 (7): S230
266. Moxey-Mims MM, Kay C, Light JA, et al. Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506). Transplantation 1998; 65 (5): 617-9
267. Backman L, Levy MF, Klintmalm G. Whole-blood and plasma levels of FK 506 after liver transplantation: results from the US Multicenter Trial. FK506 Multicenter Study Group. Transplant Proc 1995; 27 (1): 1124
268. Backman L, Nicar M, Levy M, et al. FK506 trough levels in whole blood and plasma in liver transplant recipients: correlation with clinical events and side effects. Transplantation 1994; 57 (4): 519-25
269. Bottiger Y, Brattstrom C, Tyden G, et al. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br J Clin Pharmacol 1999; 48 (3): 445-8
270. Jain AB, Todo S, Fung JJ, et al. Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. Transplant Proc 1991; 23 (6): 3023-5
271. Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration. Japanese FK 506 Study Group. Transplant Proc 1991; 23 (6): 3085-8
272. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62 (7): 920-6
273. Laskow DA, Vincenti F, Neylan JF, et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 1996; 62 (7): 900-5
274. Przepiorka D, Nash RA, Wingard JR, et al. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. Biol Blood Marrow Transplant 1999; 5 (2): 94-7
275. Sandborn WJ, Lawson GM, Cody TJ, et al. Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue. Hepatology 1995; 21 (1): 70-6
276. Schwartz M, Holst B, Facklam D, et al. FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization. Transplant Proc 1995; 27 (1): 1107
277. Takahara S, Kokado Y, Kameoka H, et al. Monitoring of FK 506 blood levels in kidney transplant recipients. Transplant Proc 1994; 26 (4): 2106-8
278. Undre NA, van Hooff J, Christiaans M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc 1999; 31 (1-2): 296-8
279. Winkler M, Pichlmayr R, Neuhaus P, et al. Optimal FK 506 dosage in patients under primary immunosuppression following liver transplantation. Transpl Int 1994; 7 Suppl. 1: S58-63
280. Winkler M, Christians U. A risk-benefit assessment of tacrolimus in transplantation. Drug Saf 1995; 12 (5): 348-57
281. Venkataramanan R, Shaw LM, Sarkozi L, et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol 2001; 41 (5): 542-51
282. Staatz C, Taylor P, Tett S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant 2001; 16 (9): 1905-9
283. Winkler M, Wonigeit K, Undre N, et al. Comparison of plasma vs whole blood as matrix for FK 506 drug level monitoring. Transplant Proc 1995; 27 (1): 822-5
284. Ringe B, Braun F, Lorf T, et al. Tacrolimus and mycophenolate mofetil in clinical liver transplantation: experience with a steroid-sparing concept. Transplant Proc 1998; 30 (4): 1415-6
285. Tsunoda SM, Aweeka FT. The use of therapeutic drug monitoring to optimise immunosuppressive therapy. Clin Pharmacokinet 1996; 30 (2): 107-40
286. Armstrong VW, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem 2001; 34 (1): 9-16
287. Shaw LM, Holt DW, Keown P, et al. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin Ther 1999; 21 (10): 1632-52
288. Kahan BD, Keown P, Levy GA, et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002; 24 (3): 330-50
289. Oellerich M, Armstrong VW, Schutz E, et al. Therapeutic drug monitoring of cyclosporine and tacrolimus: update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Clin Biochem 1998; 31 (5): 309-16
290. Alak AM, Moy S, Cook M, et al. An HPLC/MS/MS assay for tacrolimus in patient blood samples: correlation with results of an ELISA assay. J Pharm Biomed Anal 1997; 16 (1): 7-13
291. Christians U, Jacobsen W, Serkova N, et al. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J Chromatogr B Biomed Sci Appl 2000; 748 (1): 41-53
292. Deters M, Kirchner G, Resch K, et al. Simultaneous quantification of sirolimus, everolimus, tacrolimus and cyclosporine by liquid chromatography-mass spectrometry (LC-MS). Clin Chem Lab Med 2002; 40 (3): 285-92
293. Keevil BG, McCann SJ, Cooper DP, et al. Evaluation of a rapid micro-scale assay for tacrolimus by liquid chromatography-tandem mass spectrometry. Ann Clin Biochem 2002; 39 (Pt 5): 487-92
294. Lensmeyer GL, Poquette MA. Therapeutic monitoring of tacrolimus concentrations in blood: semi-automated extraction and liquid chromatography-electrospray ionization mass spectrometry. Ther Drug Monit 2001; 23 (3): 239-49
295. Salm P, Taylor PJ, Clark A, et al. High-performance liquid chromatography-tandem mass spectrometry as a reference for analysis of tacrolimus to assess two immunoassays in patients with liver and renal transplants. Ther Drug Monit 1997; 19 (6): 694-700
296. Streit F, Armstrong VW, Oellerich M. Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood. Clin Chem 2002; 48 (6 Pt 1): 955-8
297. Taylor PJ, Salm P, Lynch SV, et al. Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2000; 22 (5): 608-12
298. Volosov A, Napoli KL, Soldin SJ. Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography: tandem mass-spectrometry. Clin Biochem 2001; 34 (4): 285-90
299. Zhang Q, Simpson J, Aboleneen HT. A specific method for the measurement of tacrolimus in human whole blood by liquid chromatography/tandem mass spectrometry. Ther Drug Monit 1997; 19 (4): 470-6
300. Braun F, Peters B, Schutz E, et al. Therapeutic drug monitoring of tacrolimus early after liver transplantation. Transplant Proc 2002; 34 (5): 1538-9
301. Jorgensen K, Povlsen J, Maden S, et al. C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol Dial Transplant 2002; 17: 1487-90
302. Cantarovich M, Fridell J, Barkun J, et al. Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus. Transplant Proc 1998; 30 (4): 1460-1
303. Wong KM, Shek CC, Chau KF, et al. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am J Kidney Dis 2000; 35: 660-6
304. 0-4 in monitoring of tacrolimus in stable kidney transplant patients. Transplant Proc 2002; 34: 3173-5
305. Ku YM, Min DI. An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants. Ther Drug Monit 1998; 20 (2): 219-23
306. Stolk LM, Van Duijnhoven EM, Christiaans MH, et al. Evaluation of prediction of tacrolimus area under the curve by trough concentrations [abstract]. Br J Clin Pharmacol 2002; 53 (5): 554
307. Jorgensen KA, Povlsen JV, Poulsen JH. Optimal time for determination of blood tacrolimus level. Transplant Proc 2001; 33 (7-8): 3164-5
308. Uchida K, Tominaga Y, Haba T, et al. Usefulness of monitoring of AUC(0-4h) during the induction period of immunosuppressive therapy with tacrolimus after renal transplantation. Transplant Proc 2002; 34 (5): 1736-7
309. Dambrin C, Klupp J, Morris RE. Pharmacodynamics of immunosuppressive drugs. Curr Opin Immunol 2000; 12 (5): 557-62
310. Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 1995; 17 (6): 584-91
311. Halloran PF. Molecular mechanisms of new immunosuppressants. Clin Transplant 1996; 10 (1 Pt 2): 118-23
312. Halloran PF, Kung L, Noujaim J. Calcineurin and the biological effect of cyclosporine and tacrolimus. Transplant Proc 1998; 30 (5): 2167-70
313. Yatscoff RW, Aspeslet LJ. The monitoring of immunosuppressive drugs: a pharmacodynamic approach. Ther Drug Monit 1998; 20 (5): 459-63
314. Koefoed-Nielsen P, Jorgensen K. Alterations in calcineurin phosphatase activity in tacrolimus-treated renal transplant patients. Transplant Proc 2002; 34 (5): 1743-4
315. Koefoed-Nielsen PB, Gesualdo MB, Poulsen JH, et al. Blood tacrolimus levels and calcineurin phosphatase activity early after renal transplantation. Am J Transplant 2002; 2 (2): 173-8
316. Kung L, Halloran PF. Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. Transplantation 2000; 70 (2): 327-35
317. Dumont RJ, Ensom MH. Methods for clinical monitoring of cyclosporin in transplant patients. Clin Pharmacokinet 2000; 38 (5): 427-47
318. Andersson U, Hallden G, Persson U, et al. Enumeration of IFN-gamma-producing cells by flow cytometry: comparison with fluorescence microscopy. J Immunol Methods 1988; 112 (1): 139-42
319. Jung T, Schauer U, Heusser C, et al. Detection of intracellular cytokines by flow cytometry. J Immunol Methods 1993; 159 (1-2): 197-207
320. Assenmacher M, Schmitz J, Radbruch A. Flow cytometric determination of cytokines in activated murine T helper lymphocytes: expression of interleukin-10 in interferon-gamma and in interleukin-4-expressing cells. Eur J Immunol 1994; 24 (5): 1097-101
321. Picker LJ, Singh MK, Zdraveski Z, et al. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood 1995; 86 (4): 1408-19
322. Prussin C, Metcalfe DD. Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. J Immunol Methods 1995; 188 (1): 117-28
323. Rostaing L, Puyoo O, Tkaczuk J, et al. Differences in Type 1 and Type 2 intracytoplasmic cytokines, detected by flow cytometry, according to immunosuppression (cyclosporine A vs tacrolimus) in stable renal allograft recipients. Clin Transplant 1999; 13 (5): 400-9
324. Sewell WA, North ME, Webster AD, et al. Determination of intracellular cytokines by flow-cytometry following whole-blood culture. J Immunol Methods 1997; 209 (1): 67-74
325. van den Berg AP, Twilhaar WN, van Son WJ, et al. Quantification of immunosuppression by flow cytometric measurement of intracellular cytokine synthesis. Transpl Int 1998; 11 Suppl. 1: S318-21
326. Ahmed M, Venkataraman R, Logar AJ, et al. Quantitation of immunosuppression by tacrolimus using flow cytometric analysis of interleukin-2 and interferon-gamma inhibition in CD8(-) and CD8(+) peripheral blood T cells. Ther Drug Monit 2001; 23 (4): 354-62
327. van den Berg AP, van Son WJ, Haagsma EB, et al. Prediction of the inhibition of IL-2 production by calcineurin inhibitors. Transplant Proc 2001; 33 (1-2): 1076-7
328. Ahmed M, Venkataramanan R, Logar AJ, et al. Quantitation of immunosuppression by FK506 using flow cytometric analysis of IL-2 and INF-gamma inhibition in peripheral blood cells [abstract]. Transplantation 2000; 69: S393
329. Klupp J, Dambrin C, Regieli J, et al. New approach in drug development: whole blood pharmacodynamic assays reflect biological activities of tacrolimus. Transplant Proc 2001; 33 (3): 2172